Background: Intranasal administration of high amount of allergen was shown to induce tolerance and to reverse the allergic phenotype. However, mechanisms of tolerance induction via the mucosal route are still unclear. Objectives: To characterize the therapeutic effects of intranasal application of ovalbumin (OVA) in a mouse model of bronchial inflammation as well as the cellular and molecular mechanisms leading to protection upon re-exposure to allergen. Methods: After induction of bronchial inflammation, mice were treated intranasally with OVA and re-exposed to OVA aerosols 10 days later. Bronchoalveolar lavage fluid (BALF), T cell proliferation and cytokine secretion were examined. The respective role of CD4 1 CD25 1 and CD4 1 CD25 2 T cells in the induction of tolerance was analysed. Results: Intranasal treatment with OVA drastically reduced inflammatory cell recruitment into BALF and bronchial hyperresponsiveness upon re-exposure to allergen. Both OVA-specific-proliferation of T cells, T h 1 and T h 2 cytokine production from lung and bronchial lymph nodes were inhibited. Transfer of CD4 1 CD25 2 T cells, which strongly expressed membrane-bound transforming growth factor b (mTGFb), from tolerized mice protected asthmatic recipient mice from subsequent aerosol challenges. The presence of CD4 1 CD25 1 (Foxp3 1 ) T cells during the process of tolerization was indispensable to CD4 1 CD25 2 T cells to acquire regulatory properties. Whereas the presence of IL-10 appeared dispensable in this model, the suppression of CD4 1 CD25 2 mTGFb
Introduction
Although T h 2 polarization cannot fully explain a complex allergic condition such as asthma (1) , allergen-specific immunotherapy (SIT) in human was shown to derive the allergen-specific T h 2 immune response towards a T h 1 response (2) (3) (4) and in parallel to enhance a T regulatory cell response based on activation of IL-10-producing CD4 + CD25 + T cells (5) (6) (7) . In addition, several studies demonstrated the efficacy of SIT not only in improving asthma symptoms (8, 9) but also in delaying the progression from allergic rhinitis to asthma in children (10) . Hence, induction of tolerance to allergen appears as an efficient treatment strategy to establish both an early prophylactic as well as a therapeutic control of the specific mechanisms leading to allergic inflammation.
In naive animals, application of high-dose allergen on the respiratory or nasal mucosa was able to hamper the development of airway hyperresponsiveness (AHR) and/or T h 2-polarized responses (11) (12) (13) . Two cell lineages were considered key players in the induction of immune tolerance to allergen: dendritic cells (DCs) and CD4 + T cells (14) . In prophylactic models, the development of respiratory tolerance was initiated by uptake of antigen in the lungs by immature DC that continuously sampled foreign antigens in the bronchial mucosa (15) . As proposed in early studies, after exposure to ovalbumin (OVA), immature pulmonary DC migrate to the draining bronchial lymph nodes (BLN) where they mature and initiate a phase of allergen-specific T-cell activation, proliferation and expansion, followed by T-cell depletion from lymphoid organs. A stable population of T cells could survive but remained refractory to antigenic re-exposure (anergy) (12, 14, 16) .
Whereas nasal application of allergen or allergen-derived peptides significantly improved established systemic hypersensitivity to OVA or phospholipase A 2 (16, 17) , the possibility of reducing bronchial inflammation in established asthma via the nasal route is still debated (13, 18) . Mechanisms of protection are yet incompletely understood although a role for IL-10, transforming growth factor (TGF) b and CD25
+ T cells has been suggested (19) (20) (21) (22) (23) . Furthermore, we have recently shown that CD4 + CD25 + (Foxp3 + ) T-cell depletion fully abrogated tolerance induction via the intranasal route in an experimental model of asthma (24) . Therefore, to evaluate the therapeutic potential of antigen SIT via the nasal route and to better understand the mechanisms of induction of tolerance to allergen, we further dissected our experimental mouse model of asthma to OVA that displays full blown features of reversible airway inflammation and provided conditions compatible with allergen seasonal exposure in human.
Methods

Induction of asthma and intranasal treatment
Six-to 8-week-old BALB/c mice (Harlan, Horst, The Netherlands) were sensitized twice at day 0 (D0) and D14 by intraperitoneal (i.p.) injections of 10 lg OVA (LPS <15 pg mg À1 ; Fluka, Buchs, Switzerland) adsorbed on 1 mg aluminum hydroxide (Sigma Chemicals, St Louis, MO, USA). At D24, D26 and D28, animals were exposed to a single aerosol of OVA in PBS (0.25%) (Fig. 1 window) . Aerosolization was generated by a nebulizer (De Vilbiss; Sunrise medical GmBH, Malsch, Germany) for 20 min. At D38, 39 and 40 mice were treated intranasally with OVA 0.5 mg, 1.0 mg or 1.5 mg [OVA intranasal treatment (INT) group] or PBS (control group; PBS Fig. 1 . INT with OVA protects against cell recruitment into BALF upon OVA aerosol challenge. Total BALF cell number (A and D), relative eosinophil count in % (B and E) and mononuclear cell subpopulations number (C and F) in BALF harvested after INT (D47) or after challenge (D57), in animals treated intranasally with 0.5, 1.0 or 1.5 mg OVA versus PBS. *P < 0.05; **P < 0.01; ***P < 0.001. Window: model's treatment scheme; crosses indicate sacrifice. /J) (Charles River, France) maintained in pathogen-free environment were treated following the same protocol.
Bronchoalveolar lavage and AHR
Bronchoalveolar lavage was performed by injecting a total of 3 ml PBS (6 3 500 ll) into the lung. Approximately 10 5 cells in 100 ll were centrifuged on glass plates (Cytospin; Shandon scientific, Cheshire, U.K) and then stained with DiffQuik according to the manufacturer's recommendations (Baxter Dade, Dudingen, Switzerland). A differential count of 200 cells was performed using standard morphological criteria. AHR was measured in conscious unrestrained mice using barometric whole-body plethysmography (Buxco; EMKA technologies, Paris, France). Respiratory pressure curves were recorded in response to inhaled methacholine (Sigma Chemicals).
Proliferation assay
Proliferation assays were done as previously described (16) . Briefly, 1 3 10 5 BLN cells or 5 3 10 5 splenocytes were stimulated with or without 5 lg ml À1 OVA for 4 days, and cell proliferation was measured by 3 H-thymidine incorporation. Alternatively, CD4 + -enriched T cells (using magnetic beads from BD PharMingen, San Diego, CA, USA) from spleens of DO11.10 mice were labelled with carboxyfluorescein succinimidyl ester (CFSE) (Molecular probes, Invitrogen, Carlsbad, CA, USA) (25) . At D54, 3 3 10 6 KJ1-26 + CD4 + T cells were injected into the tail vein of asthmatic BALB/c mice following previous protocols (26) . Recipient mice were sacrificed at Mice were sacrificed at D57 and single-cell suspension of BLN were labelled with surface antibodies against KJ1-26 (DO11.10 specific) (BD PharMingen). Samples were analysed on a FACScaliburâ and fluorescence was determined using CellQuestâ software (BD Biosciences). Numbers indicate percentage of cells undergoing more than one, one or no division. *P < 0.05; **P < 0.01; ***P < 0.001.
CD4
+ CD25
À mTGFb + T cells transfer tolerance 19 D57 (3 days post-aerosol challenges). CFSE-labelled KJ1-26 + T-cell divisions were detected by flow cytometry.
Antibody isotypes
Serum IgE, IgG1 and IgG2a antibody response was determined by ELISA as described (16, 27 
CD25
À cells were re-suspended in NaCl 0.9% and 100 ll were injected in the tail vein of OVAsensitized mice at D35. Recipient mice were challenged with OVA aerosol 1, 3 and 5 days after cell transfer and sacrificed 3 days later (D43).
Anti-CD25 mAb PC61 and CD25 + T cells depletion
Anti-mouse CD25 mAb PC61 (rat IgG1, kind gift from Dr. A. Wilson; Ludwig Institute, Epalinges, Switzerland) was purified from culture supernatant on protein G sepharose column. Mice were treated i.p. with 1 mg PC61 at days 31, 38 and 45 ( Fig. 7A) . A single i.p. treatment with 1 mg PC61 yielded >80% CD4 + CD25 + T cells depletion in PBMC and spleen during 7 days (24).
Flow cytometry
IL-10 expression was monitored using the 'MACS Mouse IL-10 secretion assay kit' (Miltenyi Biotech). According to the manufacturer, single-cell suspensions from BLN or lungs stimulated for 3 days with OVA (125 lg ml
À1
) were labelled with antibodies to IL-10, CD4 and CD45R/B220 (BD PharMingen). IL-10-secreting cells were further labelled with anti-PE magnetic microbeads and enriched over a MACS separator system. Membrane-bound transforming growth factor b (mTGFb) expression on BLN cells was performed with an anti-TGFb mAb (IQ Products, Groningen, The Netherlands). Samples were analysed on a FACScaliburâ and fluorescence intensity was determined using CellQuestâ software (both from BD Biosciences).
Statistical analysis
Results are expressed as mean 6 SD of four to six mice per group. Each experiment was done at least three times. Significance of differences between means was determined by Student's t-test using Prism 4.00 software for Windows (GraphPad Software Inc., La Jolla, CA, USA).
Results
INT with OVA inhibits inflammatory cell recruitment into bronchoalveolar lavage fluid (BALF) upon re-exposure to OVA.
To induce bronchial inflammation, mice were first sensitized by two i.p. injections of OVA and a series of three OVA aerosols as described in Methods. At day 31, these mice displayed a strong eosinophil recruitment (79.07 6 1.99%, 1.66 6 0.32 3 10 6 eosinophils in the BALF as compared with control PBS-aerosolized mice: 3.12 6 0.42%; 0.03 6 0.003 3 10 6 ). OVA-aerosolized mice were then randomly assigned to PBS INT or OVA INT group at day 38 and treated intranasally with OVA in a dose-escalating schedule (0.5, 1.0 and 1.5 mg) every day for 3 days from D38. Control mice received PBS alone. One week after INT with OVA (D47), an enhanced inflammatory cell recruitment (total cell and eosinophil count) was observed in BALF, which was inversely correlated to the intranasal dose of OVA ( Fig. 1A-C) . On the contrary, after challenge with OVA aerosols (D57), inflammatory cell recruitment was markedly impaired, however, without evidence of a dose effect ( Fig. 1D-F ). These data clearly indicated that INT with OVA was able to protect allergen re-exposed mice from recruiting eosinophils and, to a lesser extent, lymphocytes into the bronchial lumen, both major players of airway inflammation. Inhibition of eosinophil recruitment at D57 was preceded by apparent activation of inflammation post-INT in an inversely correlated dose response at D47.
To evaluate the duration of protection, the interval between INT with OVA and re-exposure to OVA aerosols was extended from 10 to 18 or 32 days. Longer time intervals further attenuated BALF eosinophil recruitment ( Fig. 2A) . Moreover, when aerosol challenges with OVA were repeated twice at 30-day interval, eosinophil recruitment appeared to be durably and strongly inhibited (Fig. 2B) . Inhibition of eosinophil recruitment into BALF was antigen specific since INT with human albumin (HAS) in OVA-sensitized mice had no effect on eosinophil recruitment into BALF upon OVA aerosol challenge (Fig. 2C and D) .
CD4
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OVA INT inhibits AHR, EPO production and cell proliferation
To determine whether inhibition of eosinophil influx into BALF was also accompanied by a decrease in other parameters of lung inflammation, AHR, EPO and lymphocytes proliferation were assessed after re-exposure to OVA aerosols (D57). At this time point, AHR and EPO activity significantly decreased in OVA INT mice ( Fig. 2E and F) , whereas significantly higher levels of EPO were detected at D47 (Fig. 2F) . These data suggested that INT with OVA not only inhibited eosinophil recruitment into bronchial lumen but also in lung tissue itself. Finally, T-cell proliferation assays to OVA led to marked allergen-specific T-cell hyporesponsiveness at D57 (Fig. 2G) . To further support this observation, CFSE-labelled OVA transgenic T cells from D011.10 mice were transferred into OVA INT mice at D54. Tracked by cytofluorimetry at D57, they divided less actively as compared with PBS INT mice (Fig. 2H) .
OVA INT inhibits IgE production upon allergen re-exposure and generates competitive anti-OVA IgG After OVA challenge (D57), a strong production of OVA-specific IgE was induced in control mice, whereas IgE in OVA INT mice remained at baseline level in contrast to OVA-specific IgG1 (Fig. 3A and B) . IgG2a production was similar in OVA-and PBS-treated mice (Fig.  3C ). To evaluate a potential competition between OVA-specific IgG and IgE for binding sites, an anti-IgE capture ELISA was performed as an alternative approach. In this condition, we observed a strong IgE production in the OVA INT group at D47, which remained constant after challenge (D57) (Fig. 3D) , indicating that the low IgE levels observed after challenge in OVA INT mice resulted both from inhibition of IgE production and competition with specific anti-OVA IgG. # compared with D47. *P < 0.05; **P < 0.01; ***P < 0.001. 
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OVA INT prevents T h 2 cytokine production upon re-exposure to OVA
In supernatants of lung homogenates, IL-4, IL-5 and IL-10 production followed the same kinetics: a vigorous induction after INT (D47) and a marked inhibition upon re-exposure to OVA in OVA INT mice (D57) (Fig. 4A-C) , in contrast to TGFb strongly stimulated after OVA re-exposure (Fig. 4D) . IFNc production did not significantly differ between groups at D47 and D57 (Fig. 4E) . In the supernatants of BLN or lung cells stimulated with OVA, IL-4, IL-5, IL-10, IL-13 and IFNc, production did not significantly differ at D47 between OVA INT mice and controls ( Fig. 5A-E T cells at D47, whereas at D57 CD4 + IL-10 + T cells expansion was markedly limited (Fig. 5F ).
+ CD25 À T cells protect recipient mice against OVA challenge
To identify the key regulatory cell subsets, we first performed a preliminary transfer experiment with total CD4 + T cells from BLN and lung from OVA INT mice into OVA-sensitized recipients. Transfer efficiently inhibited eosinophil recruitment into the BALF of recipient asthmatic mice at D57 (Fig. 6A  and B) . OVA-specific serum IgE as well as IL-4 and IL-10 in lung supernatants were also down-regulated ( Fig. 6C-E (Fig. 6F) . As measured by flow cytometry, the frequency of CD4 + CD25 À mTGFb + T cells was significantly enhanced in OVA INT mice at D57 (Fig. 6G ) in contrast to that of CD4 +
CD25
+ mTGFb + T cells that did not differ between groups (data not shown).
CD4
+ CD25 À mTGFb + T cells play a key role in the induction of tolerance As suggested above (Fig. 6G) , mTGFb 
+ CD25 À mTGFb + T cells transfer tolerance inflammatory than BALF from animals transferred with mTGFb-depleted CD4 + CD25 À T cells, as expressed by total inflammatory cell number and eosinophil number (Fig. 6H ). This strongly indicated that CD4 + CD25 À mTGFb + T cells played a key role in the induction of intranasal tolerance to OVA. Nonetheless, the depletion of CD4 + CD25 À mTGFb + T cells only led to partial reversion of tolerance, suggesting that mTGFb + -expressing CD4 + CD25 À T cells may not be the sole partners involved in this phenomenon.
+ CD25 + T cells are necessary for the induction of CD4 + CD25 À T cells with regulatory activity
As previously shown, the deletion of CD4 + CD25 + T cells prior to INT with OVA completely abrogated the induction of tolerance (24) . To verify the hypothesis that CD4 + CD25 + T cells (>80% Foxp3 + ) were indispensable intermediates in the mechanisms leading to the induction of CD4 + CD25 À T cells with regulatory properties, OVA-sensitized mice were treated with anti-CD25 mAb PC61 or with PBS as control at D31 prior to INT with OVA, then at D38 and D45 and finally reexposed to OVA aerosols (Fig. 7A ). Mice were sacrificed at D52 and CD4 + CD25 À T cells purified by magnetic cell sorting. CD4 + CD25 À T cells from PC61 pre-treated or control animals were then transferred to OVA-sensitized/OVA aerosol challenged mice at D35. Transferred animals were re-exposed to OVA aerosols and BALF analysed for inflammatory cell count (Fig. 7B) . There was no significant difference between non-transferred control animals and CD25-depleted/CD4
+ CD25 À T cell-transferred animals. In contrast, BALF from mice transferred with CD4 + CD25 À T cells from CD25 non-depleted animals were significantly less inflammatory as measured by eosinophil count. This strongly suggested that CD4 + CD25 + T regulatory cells were indispensable for induction of tolerance and required for CD4 + CD25 À T cells education into cells with regulatory properties.
Induction of tolerance via the nasal route also occurs in the absence of IL-10 expression
To evaluate the role of IL-10 in the induction of tolerance, we took advantage of the C57BL/10 IL-10 À/À knockout model (Fig. 8 ). After sensitization with OVA and exposure to 
CD25
À mTGFb +/À T cells from donor mice at day 35. BALF were collected after OVA challenge (aerosols) at day 43 and absolute number of eosinophils, macrophages and lymphocytes in BALF were determined. *P < 0.05; **P < 0.01; ***P < 0.001.
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OVA aerosols, mice were treated intranasally either with OVA or with PBS as described in Fig. 1 . As demonstrated in the BALB/c IL-10 +/+ model, a marked down-regulation of total inflammatory cells and eosinophils in BALF was observed not only in C56BL/10 IL-10 +/+ mice ( Fig. 8A and C) but also in C56BL/10 IL-10 À/À mice ( Fig. 8B and D) upon INT with OVA and re-exposure to OVA aerosols at D57. There was no significant difference in BALF infiltration between IL-10 À/À mice and IL-10 +/+ mice. This strongly suggested that IL-10 may not play a unique role in the down-regulation of inflammatory infiltrate in BALF in this model and especially in the downregulation of eosinophil recruitment.
Discussion
We demonstrated in this study the ability of nasal application of OVA to protect against further re-exposure to OVA aerosols in a therapeutic model of asthma. Mucosal delivery of OVA via the nasal route markedly reduced eosinophil and other inflammatory cell recruitment into BALF and bronchial airways, as well as AHR, in an antigen-specific manner. T h 2 and T h 1 cytokines were strongly inhibited, and OVAspecific T cell proliferative response was markedly decreased, establishing a state of tolerance to OVA. Protection upon re-exposure to OVA was sustained up to 32 days after nasal application of allergen. Moreover, tolerance to allergen re-exposure could be transferred by CD4 + CD25 À T cells from tolerized mice. In vivo, in the absence of CD4 + CD25 + (Foxp3 + ) T cells, CD4 + CD25 À T cells from tolerized mice were in contrast unable to acquire regulatory properties and to transfer tolerance. A significant fraction of tolerogenic CD4 + CD25 À T cells expressed mTGFb, which appeared to play a significant role in the induction of tolerance in contrast to IL-10.
Taken together, our data supported a down-regulation of both T h 1 and T h 2 cytokines rather than a strict T h 2 to T h 1 shift, an effect compatible with observations done in models of allergen SIT (30, 31) and in venom immunotherapy (32) . These results also demonstrated the potential of mucosal delivery of allergen to efficiently down-regulate an established bronchial inflammation and to improve asthma. In this regard, our observations are in line with a previously published model demonstrating the superior capacity of intranasal immunotherapy over intradermal immunotherapy in down-regulating airway allergic inflammation (13) . However, in contrast to our approach, Takabayashi et al. were not able to down-regulate T h 2 inflammation at a systemic level. The higher doses of OVA used in our model may account for this difference. Furthermore, in our approach, INT with OVA was not only able to induce long-term protection (Fig. 2) 
CD25
À T cells were purified from lungs and BLN from donor mice at day 52 and transferred into recipient mice at day 35. OVA-sensitized recipient mice were transferred with CD4 + CD25 À T cells at day 35, challenged with OVA aerosols at days 36, 37 and 38 and sacrificed at day 43. (B) Number of eosinophils in BALF as a function of the various conditions were described under (A). Crosses indicate sacrifice. **P < 0.01; ***P < 0.001.
CD4
+ CD25 À mTGFb + T cells transfer tolerance resistance to a second series of allergen challenges. This sustained effect of INT with OVA strongly suggested that a long-term suppressive memory response was taking place, in agreement with the long-term protection provided by subcutaneous immunotherapy in mouse (33) and in human (8) .
INT with OVA abrogated the rise in OVA-specific IgE present in control mice after re-exposure, whereas in contrast IgG1 increased. Similarly, after intranasal but not oral tolerance in a prophylactic murine model of asthma, T h 2 cytokine secretion by allergen-specific T cells were down-regulated although IgG1 increased concomitantly (34) .These findings were globally in agreement with allergen SIT to respiratory or hymenoptera allergens in human, associated with an increase in serum allergen-specific IgG1, IgG4 and IgA (5, 35, 36) . In vitro, mouse IgG1 were able to block human IgE interaction with allergen by competing on similar Bet v 1 epitopes (37). IgG1 may thus take part to the protection observed in OVA INT animals upon re-exposure to allergen.
At D47, i.e. 1 week after OVA INT, we observed a marked enhancement of the inflammatory response in lungs and BLN, in particular of the T h 2 cytokine response (Figs 4 and 5). Eosinophil recruitment into BALF was strongly stimulated with the lowest dose of OVA (0.5 mg) as compared with the highest dose (1.5 mg) (Fig. 1) , although both treatment levels led to significant and comparable impairment in eosinophil recruitment upon OVA aerosol challenges at D57. These results are reminiscent of previous mice and human immunotherapy studies demonstrating that prior to tolerance induction, a transient inflammatory phase may occur (12, 36, 38) . Lung inflammation and T-cell activation in the early phase of nasal allergen SIT appears therefore a pre-requisite to immune response down-regulation.
The mechanisms underlying the down-regulation of the allergic airway response in our model still need to be fully characterized, but at that stage, our data suggest a role for both CD4
+ CD25 + and CD4 + CD25 À T cells. Indeed, transfer of CD4 + T cells from OVA INT mice reproduced the effect of INT with OVA (Fig. 6) . Moreover, protective effects were fully reproduced by the transfer of CD4 + CD25 À T cells and only when isolated from mice treated intranasally with OVA. This strongly suggested that nasal application of OVA was able to induce a subset of CD4 + T cells able to transfer tolerance, i.e. to express regulatory properties. Our observations are reminiscent of previous reports in models of autoimmunity, where the in vivo transfer of CD4 + CD25 À T cells was able to induce protection (39) (40) (41) 
Foxp3
À T regulatory cells is still unclear. Our data support a potential role for TGFb, a key regulatory cytokine involved in the protection upon re-exposure to allergen (42, 43) . This was strongly suggested by the markedly enhanced production of TGFb in lung supernatants ex vivo (Fig. 4D) , although we cannot rule out that part of this TGFb secretion may also be due to non-immune cells (44) . Furthermore, we know from our previous publication that CD4 + CD25 + Foxp3 + T cells express high level of mTGFb, suggesting a role for mTGFb in the induction of CD4 + CD25 À with regulatory properties (24) . This interpretation has been previously supported by a model of aerosolized antigen-induced tolerance involving cell-cell contact with regulatory CD4 + T cells that co-express mTGFb and Foxp3 (20) . A synergy between mTGFb and Cytotoxic T-Lymphocyte Antigen 4 in T regulatory cellsmediated suppression of proliferation of CD25 À effector T cells has been previously demonstrated (45) . Furthermore, INT with OVA is associated with a significant enhancement of the expression of mTGFb on CD4 + CD25 À T cells (Fig. 6) (42) .
The anti-inflammatory role of IL-10 is in contrast debatable in our model. Indeed, IL-10 production in lung homogenates or in supernatants from BLN and lung cell culture rose markedly after INT with OVA but sharply dropped after re-exposure to OVA aerosols (Fig. 5) . These findings correlated with an increased frequency of CD4 + IL-10 + T cells in lungs and BLN after INT with OVA contrasting with a marked decrease after OVA challenges. Our data may possibly be representative of IL-10 production by T regulatory cells as suggested in prophylactic models (16, 19) but may also result from IL-10 production by OVA-specific T h 2 effector cells (46) . Furthermore, tolerance induction to OVA was obtained in IL-10 À/À mice, although in a different genetic background, showing that IL-10 was not unique in the process leading to tolerance. These data were in agreement with our previous observations indicating that the frequency of CD4 + CD25 À IL-10 + T cells from tolerized mice was low (as compared with CD4 + CD25 + T cells) and did not significantly differ from the frequency of CD4 + CD25 À IL-10 + T cells in non-tolerized animals (24) . We cannot, however, fully exclude a possibly redundant anti-inflammatory role for IL-10 or an activity on other parameters than those considered here (lung eosinophilia, IgE production). We indeed showed an enhanced production of IL-17 in the lungs of tolerized animals (24), a result that may suggest a regulatory contribution of this cytokine in turning down the T h 2 immune response of asthmatic mice in the absence of concomitant enhancement of the T h 1 response (47) . On the one hand, IL-17 induction in tolerized mice may support an immunoregulatory activity of IL-17 in dampening the T h 2 airways inflammation (47) (48) (49) . On the other hand, IL-17 secretion into the lungs would be a logical consequence of the concomitant action of TGF b and IL-6 leading to the generation of T h 17 cells (50) . A better understanding of the IL-17 response and involvement in tolerance induction is ongoing in our laboratory.
Taken together, our model of tolerance in asthma contributed to demonstrate that INT with OVA led to the induction of CD4 + CD25 À T cells with regulatory properties under the control of CD4 + CD25 + Foxp3 + T cells. The fine mechanisms leading to the generation of T regulatory cells appeared to involve mainly TGFb/mTGFb expression as key players, the respective roles of which will have to be further analysed. This model also strongly supports allergen-specific induction of tolerance based on a mucosal approach in human with allergic asthma.
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